A 25-year-old Nevada boy COVID-19 in April and June, genomic sequencing confirms the differences between variants, researchers reported in a peer-reviewed journal.
In this case, which reached the media last August after the publication of the researchers’ printed script, the type tested positive for SARS-CoV-2 on April 18 and June 5, with two negative tests in May and the timing of the infection resulting in a more serious illness, reported Mark Pandori, PhD, of the Reno School of Medicine at the University of Nevada , and his colleagues, writing in The Lancet Infectious Diseases.
The first widely reported case of co-infection through COVID-19 occurred in a Hong Kong boy in August, however, Hong Kong patient infections occurred in March and August and at the moment was asymptomatic.
“It is vital to note that this is a singular discovery and does not allow this phenomenon to become widespread,” Pandori said in a statement. “This also strongly suggests that other people who have tested positive for SARS-CoV-2 continue to take serious precautions regarding the virus, adding social estating, dressed in mask and hand washing. “
An accompanying editorial in Lancet Infections Disease written through Akiko Iwasaki, PhD at Yale University School of Medicine in New Haven, Connecticut, noted that while some cases of reinfection are known, they have implications for public fitness.
On the one hand, he wrote Iwasaki, immunity “not necessarily” to Americans of the disease after being reinfected, because this patient from Nevada and some other in Ecuador had worse effects after the time of infection. In addition, reinfection is likely underestimated, such as the “lack of evidence and large-scale follow-up” means that the formula lacks asymptomatic cases.
These cases of reinfection mean that “we cannot rely on immunity acquired through an herbal infection to confer collective immunity; this strategy is not only deadly for many, but it is also not effective,” Iwasaki wrote, and the safest path to the collective Immunity is done through a safe system and an effective vaccine.
And we just want a vaccine opposite SARS-CoV-2, Iwasaki said, because other viral isolations don’t imply that the time of infection was due to “immune evasion. “
“Lately there is no evidence that a variant of SARS-CoV-2 emerged as a result of an immune leak. For now, a vaccine will be enough to provide coverage against all circulating variants,” he wrote.
Case details
Pandori and his colleagues gave more details about the patient’s clinical details. On March 25, the patient began reporting a sore throat, cough, headache, nausea and diarrhea, and was recorded at a network checkup on April 18. His symptoms disappeared on April 27, but on May 18. On June 31, the patient went to an emergency care center for fever, headache, cough, nausea and self-informed diarrhea. On June 5, the patient’s number one care physician sent him to the emergency unit for oxygen supply, after the patient discovered he was hypoxic and short of air.
He needed an uninterrupted source of oxygen for the hospital and reported myalgia, coughing and shortness of breath. Chest x-rays showed “bilateral abnormal interstitial opacity” indicating pneumonia.
The patient tested positive for SARS-CoV-2 through the chain reaction through opposite transcriptase polymerase (RT-PCR) on April 18, followed by two negative tests after the solution of their symptoms. It then tested positive through RT-PCR on June 5. however, IgG and IgM opposed to SARS-CoV-2 were also positive.
The researchers proposed several hypotheses explaining why the timing of the infection may have been worse than the first, as a maximum dose of virus can induce a more serious disease, than reinfection caused by a more virulent virus in this patient or simply due to improved antibody-mediated disease
They observed that the patient had no immune disorder, was not taking immunosuppressive drugs and was negative for HIV by testing antibodies and RNA, with no apparent alterations in the number of cells.
The authors stated that they were unable to adopt an assessment of the immune reaction to the first infection and that they may not fully evaluate the effectiveness of immune reactions at the time of infection.
“We want more studies to see how long immunity can last for others exposed to SARS-CoV-2 and why some of these rare momentary infections are more severe,” Pandori said. “At the moment, we can only speculate, about the cause of reinfection. “
Molly Walker, associate editor-in-chief, covering infectious diseases for MedPage Today, is passionate about evidence, knowledge and public health.
This study is supported by nevada’s IDEA Biomedical Research Network and the National Institute of General Medical Sciences of NIH.
Tillett revealed any conflict of interest.
Pandori revealed any conflict of interest.
A co-author revealed that of Qiagen Digital Insights.
At MedPage Today, we are committed to ensuring that other people with disabilities can access all the content MedPage Today has to do through our online page and other properties. send an email to legal@ziffdavis. com for help. Type “ADA Request” in the thematic line of your email.